<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00572819</url>
  </required_header>
  <id_info>
    <org_study_id>2007-004083-52</org_study_id>
    <secondary_id>2007-004083-52</secondary_id>
    <nct_id>NCT00572819</nct_id>
  </id_info>
  <brief_title>Hysteroscopy After Pretreatment With Misoprostol and Estradiol Trial</brief_title>
  <official_title>Does Self-Administered Vaginal Misoprostol Result in Cervical Ripening in Postmenopausal Women After 14 Days Pre-Treatment With Estradiol?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ullevaal University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Helse Nord</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ullevaal University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate whether 1000 micrograms of self-administered vaginal
      misoprostol 12 hours before operative hysteroscopy results in effective preoperative cervical
      ripening after two weeks pretreatment with 25 micrograms daily vaginal estradiol, compared to
      placebo (lactosum monohydricum) in postmenopausal women.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome is the preoperative baseline cervical dilatation in the two treatment groups.</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference between baseline cervical dilatation at recruitment and preoperative dilatation.</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Women with cervical dilatation ≥ 5 mm.</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acceptability.</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of dilatations judged as &quot;difficult.&quot;</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of complications.</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cervical Ripening</condition>
  <arm_group>
    <arm_group_label>Misoprostol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol</intervention_name>
    <description>1000 micrograms of self-administered vaginal misoprostol compared to placebo 12 hours before operative hysteroscopy after two weeks pretreatment with 25 micrograms daily vaginal oestradiol.</description>
    <arm_group_label>Misoprostol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Vaginal lactosum monohydricum administered 24 hours in postmenopausal women, compared to misoprostol after two weeks pretreatment with 25 micrograms daily vaginal oestradiol.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All postmenopausal (&gt; one year since last menstruation) women who are referred to
             outpatient hysteroscopy with a medical indication for hysteroscopy, and who have given
             informed consent, will be eligible for study recruitment

        Exclusion Criteria:

          -  Women who do not wish to participate

          -  Women who are medically unfit for hysteroscopy

          -  Women who are medically unfit for participation in any clinical trial

          -  Women who do not have a medical indication for hysteroscopy

          -  Women who have previously had, or currently have breast or gynaecological cancer

          -  Women who have a medical contraindication for locally applied oestradiol

          -  Women who are currently using hormone therapy

          -  Women who are unable to communicate in Norwegian, and

          -  Women with a known allergy to misoprostol
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Britt-Ingjerd Nesheim, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Oslo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gynaecological Department, Ullevål University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>N-0450</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>May 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2007</study_first_submitted>
  <study_first_submitted_qc>December 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2007</study_first_posted>
  <last_update_submitted>May 22, 2009</last_update_submitted>
  <last_update_submitted_qc>May 22, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 25, 2009</last_update_posted>
  <responsible_party>
    <name_title>Britt-Ingjerd Nesheim</name_title>
    <organization>Gynaecological Department, Ullevål University Hospital, Oslo, Norway</organization>
  </responsible_party>
  <keyword>Hysteroscopy</keyword>
  <keyword>Misoprostol</keyword>
  <keyword>Postmenopausal women</keyword>
  <keyword>Cervical ripening</keyword>
  <keyword>Dilatation</keyword>
  <keyword>Sequential trial</keyword>
  <keyword>Estradiol</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>July 27, 2009</submitted>
    <returned>September 2, 2009</returned>
    <submitted>September 21, 2009</submitted>
    <returned>September 30, 2009</returned>
    <submitted>December 2, 2009</submitted>
    <returned>January 5, 2010</returned>
    <submitted>January 8, 2010</submitted>
    <returned>February 1, 2010</returned>
    <submitted>June 30, 2011</submitted>
    <returned>July 28, 2011</returned>
    <submitted>August 17, 2012</submitted>
    <returned>September 13, 2012</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

